Navigation Links
American Heart Association comment: FDA announces safety changes on labeling for some statins
Date:2/29/2012

The United States Food and Drug Administration (FDA) announced it is revising safety information on the labels of some statins (cholesterol lowering drugs).

Statins are a class of drugs that work in the liver to prevent the formation of cholesterol. They are most effective at lowering the LDL (bad) cholesterol, but also have modest effects on lowering triglycerides (blood fats) and raising HDL (good) cholesterol. High cholesterol is a risk factor for cardiovascular disease and stroke.

The FDA changes to the statin labels include:

  • Revising the drug labels to remove the need for routine periodic monitoring of liver enzymes in patients taking statins.
  • Including labeling information about some patients experiencing memory loss and confusion.
  • Warning healthcare professionals and patients of the potential risk of increased blood sugar levels and of being diagnosed with type 2 diabetes mellitus.

The announcement also alerts health care professionals to new recommendations in the lovastatin label, including drug interactions like those with drugs used to treat HIV (protease inhibitors).

"The FDA's announcement on the label changes does not question the benefit of statins to lowering cholesterol, but it does provide patients and healthcare providers the most current information about the safe use of statins," said Gordon F. Tomaselli, M.D., president of the American Heart Association.

"Not surprising, but important for practitioners with regard to routine liver function test screening, which is no longer recommended, but should be done at baseline and for symptoms. This will change practice although I will remain vigilant in people with prior history of liver disease, people who drink or who are taking multiple drugs metabolized by the liver. Also, the contraindications of use of in particular anti-HIV drugs with Mevacor (lovastatin) are important to reemphasize as is the known but infrequent increase in blood sugar in patients taking statins."

Tomaselli says "while we recommend healthy people focus on prevention using lifestyle changes rather than drug therapy whenever possible, for some people, lifestyle changes aren't enough. As with all therapies, the decision to use statins for primary or secondary prevention must include careful consideration of the risks and benefits, side-effects and cost. Working with your healthcare provider to be sure you're doing what you need to do to stay healthy is the best approach."


'/>"/>

Contact: Julie Del Barto
julie.delbarto@heart.org
214-706-1173
American Heart Association
Source:Eurekalert

Related medicine news :

1. The North American Menopause Society (NAMS) reassures many women
2. In Tougher Economy, Fewer Americans Get Colonoscopy
3. Colon Cancer Alliance and American College of Radiology demand Medicare cover virtual colonoscopy
4. Hispanic Americans Born Outside Country Have Fewer Strokes
5. Hepatitis C Now Kills More Americans Than HIV
6. American Society of Hematology statement on critical methotrexate drug shortage
7. Millions of Americans Have Untreated Hearing Loss: Study
8. More Than 4 Million Americans Have New Knee
9. 4.5 million Americans living with total knee replacement
10. More Americans Seeking Love Online: Study
11. Too Few Americans Getting Screened for Common Cancers: CDC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... ... July 21, 2017 , ... The Ellis Agency, an eastern ... Epilepsy Foundation in a community wide charity event with the goal of bringing in ... young local woman who lives with epilepsy, recently launched a charity campaign of her ...
(Date:7/21/2017)... ... 2017 , ... The Karen Miller Agency, a central Alabama ... greater Birmingham area, is joining the Chris Hammond Youth Foundation in a charity ... , The Chris Hammond Youth Foundation maintains athletic facilities in rural areas that ...
(Date:7/21/2017)... Grove, Ill. (PRWEB) , ... July 21, 2017 , ... ... & Fabric Liquid eco-friendly odor-control solution for colleges and universities at the ... safely and effectively eliminate severe cannabis and tobacco smoke odors without the use of ...
(Date:7/21/2017)... ... ... Hospital M&A activity slowed in the second quarter of 2017, according to new ... in the second quarter, up 15% from the 20 publicly announced acquisitions in the ... year-ago second quarter. Only four of the transactions disclosed a purchase price in the ...
(Date:7/21/2017)... ... July 21, 2017 , ... The Margarian Law Firm has filed a ... ginger ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand ... Gegham Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is ...
Breaking Medicine News(10 mins):
(Date:7/11/2017)... , July 11, 2017 Oramed Pharmaceuticals ... a clinical-stage pharmaceutical company focused on the development of ... Food and Drug Administration (FDA) has agreed to schedule ... completed Phase IIb trial of its oral insulin capsule ... Phase IIb trial met primary and secondary endpoints by ...
(Date:7/10/2017)... PARK, N.C. , July 10, 2017 ... $5m Convertible Note to support the development of CRISPR-Cas3 ... Tencent Holdings Limited, a leading Chinese Internet services provider, ... funding will advance multiple infectious disease product programs targeting ... Founded by Dr. Rodolphe ...
(Date:7/5/2017)... July 5, 2017   BioLife Solutions , Inc. ... and marketer of proprietary clinical grade cell and tissue ... media ("BioLife"), today announced that it has reached an ... and largest shareholder, to modify its existing credit facility ... the modification, WAVI agreed to exchange its existing $4.25 ...
Breaking Medicine Technology: